R&D channel feed

Af­ter dis­ap­point­ing in­vestors, Sil­la­Jen gets in­to trou­ble with Ko­re­an pros­e­cu­tors on sus­pect­ed in­sid­er trad­ing

6 years ago

FDA fi­nal­izes guid­ance on place­bos and blind­ing for can­cer tri­als

6 years ago
FDA+

In a bat­tered field, As­traZeneca's lu­pus drug clears piv­otal study — but can they get it ap­proved now?

6 years ago

The Wood­ford ef­fect: Tee­ter­ing on the edge, his co-in­vestors are feel­ing the pain — and they want it to stop

6 years ago

As­traZeneca wins a round in their PhI­II COPD bout with GSK — but can they catch up?

6 years ago

Bris­tol-My­ers opens up the Phase 0 path­way in test­ing its new can­cer ther­a­pies, fol­low­ing in Cel­gene’s foot­steps

6 years ago
Deals

For sale: Boston Chil­dren’s team touts a new CRISPR de­liv­ery sys­tem for triple-neg­a­tive breast can­cer — plus — af­ter test­ing it in mice and cells

6 years ago
Pharma

San­ther­a's Duchenne ef­fort gets a boost on pos­i­tive PhI­Ia for al­ter­na­tive steroid va­morolone — though there's a lot left to prove

6 years ago

Fran­chise killer: Are Re­gen­eron and Sanofi about to get hand­ed their walk­ing pa­pers on PC­SK9?

6 years ago

Out to shake up PC­SK9 mar­ket, Med­i­cines Co boasts of piv­otal PhI­II win for in­clisir­an

6 years ago

Fi­bro­Gen founder and CEO Thomas Neff dies un­ex­pect­ed­ly as lead drug nears com­mer­cial thresh­old

6 years ago

From $30M launch round to $400M buy­out deal — with $250M up­front — in 10 short months

6 years ago
Deals

Olu­mi­ant from Lil­ly, In­cyte clears third eczema study, but who will use it?

6 years ago
Pharma

FDA asks why No­var­tis took two months to launch for­mal in­ter­nal probe, af­ter AveX­is flagged da­ta ma­nip­u­la­tion

6 years ago
Pharma
FDA+

Clear­side Bio­med­ical pre­dicts its uveitis drug will be re­ject­ed, af­ter FDA re­quests more da­ta

6 years ago
FDA+

GSK's Hal Bar­ron her­alds their sec­ond pos­i­tive piv­otal for cru­cial an­ti-BC­MA ther­a­py, point­ing to a push for quick OKs in a crowd­ed field

6 years ago

Am­gen, Al­ler­gan biosim­i­lar of Roche's block­buster Rit­ux­an clears an­oth­er US piv­otal study 

6 years ago

An em­bold­ened As­traZeneca splurges $95M on a pri­or­i­ty re­view vouch­er. Where do they need the FDA to hus­tle up?

6 years ago
Pharma

Eight weeks be­tween each HIV treat­ment? GSK notch­es PhI­II win as it chas­es OK for long-act­ing reg­i­men

6 years ago

Pris­on­er #87850-053 does not get to add drug de­vel­op­er to his list of cred­its

6 years ago

Vi­en­na-based vac­cine de­vel­op­er Themis signs pact with Mer­ck for 'block­buster in­di­ca­tion'

6 years ago
Deals

MD­MA, now in Phase III, shows promise as a PTSD treat­ment

6 years ago

Pfiz­er is mak­ing a $500M state­ment to­day: Here’s how you be­come a lead play­er in the boom­ing gene ther­a­py sec­tor

6 years ago

Fu­til­i­ty analy­sis au­gurs de­feat in piv­otal tri­al test­ing of Nu­Cana's lead drug in metasta­t­ic pan­cre­at­ic can­cer

6 years ago
First page Previous page 234235236237238239240 Next page Last page
A service from the Financial Times